These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20957481)

  • 1. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
    Kim KP; Ryu MH; Yoo C; Ryoo BY; Choi DR; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):285-91. PubMed ID: 20957481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
    Reichardt P; Blay JY; Gelderblom H; Schlemmer M; Demetri GD; Bui-Nguyen B; McArthur GA; Yazji S; Hsu Y; Galetic I; Rutkowski P
    Ann Oncol; 2012 Jul; 23(7):1680-7. PubMed ID: 22357255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
    Montemurro M; Schöffski P; Reichardt P; Gelderblom H; Schütte J; Hartmann JT; von Moos R; Seddon B; Joensuu H; Wendtner CM; Weber E; Grünwald V; Roth A; Leyvraz S
    Eur J Cancer; 2009 Sep; 45(13):2293-7. PubMed ID: 19467857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
    Sawaki A; Nishida T; Doi T; Yamada Y; Komatsu Y; Kanda T; Kakeji Y; Onozawa Y; Yamasaki M; Ohtsu A
    Cancer; 2011 Oct; 117(20):4633-41. PubMed ID: 21456006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
    Shirao K; Nishida T; Doi T; Komatsu Y; Muro K; Li Y; Ueda E; Ohtsu A
    Invest New Drugs; 2010 Dec; 28(6):866-75. PubMed ID: 19730791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report.
    Dizdar O; Yalcin S
    Hepatogastroenterology; 2011; 58(107-108):859-60. PubMed ID: 21830404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nilotinib in advanced gastrointestinal stromal tumors after imatinib and sunitinib therapy.
    Dizdar O; Yalcin S
    Hepatogastroenterology; 2011; 58(112):2012-4. PubMed ID: 22024073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
    Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
    Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
    Li J; Gao J; Hong J; Shen L
    Future Oncol; 2012 May; 8(5):617-24. PubMed ID: 22646775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
    Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
    Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
    Yoon DH; Ryu MH; Ryoo BY; Beck M; Choi DR; Cho Y; Lee JL; Chang HM; Kim TW; Kang YK
    Invest New Drugs; 2012 Apr; 30(2):819-27. PubMed ID: 21104107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
    George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
    Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
    Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG
    Lancet; 2006 Oct; 368(9544):1329-38. PubMed ID: 17046465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.
    Sevinc A
    Chemotherapy; 2009; 55(2):132-6. PubMed ID: 19188713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    Montemurro M; Gelderblom H; Bitz U; Schütte J; Blay JY; Joensuu H; Trent J; Bauer S; Rutkowski P; Duffaud F; Pink D
    Eur J Cancer; 2013 Mar; 49(5):1027-31. PubMed ID: 23140824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
    Benjamin RS; Schöffski P; Hartmann JT; Van Oosterom A; Bui BN; Duyster J; Schuetze S; Blay JY; Reichardt P; Rosen LS; Skubitz K; McCoy S; Sun YN; Stepan DE; Baker L
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):69-77. PubMed ID: 20838998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
    Cauchi C; Somaiah N; Engstrom PF; Litwin S; Lopez M; Lee J; Davey M; Bove B; von Mehren M
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):977-82. PubMed ID: 22119758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
    Joensuu H; De Braud F; Grignagni G; De Pas T; Spitalieri G; Coco P; Spreafico C; Boselli S; Toffalorio F; Bono P; Jalava T; Kappeler C; Aglietta M; Laurent D; Casali PG
    Br J Cancer; 2011 May; 104(11):1686-90. PubMed ID: 21540861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to imatinib- and sunitinib-resistant GIST.
    Reichardt P
    Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.